Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gynecol Oncol. 2019 Jun;153(3):597-603. doi: 10.1016/j.ygyno.2019.03.008. Epub 2019 Mar 11.
To evaluate the efficacy and economic impact of a transfusion reduction initiative for patients undergoing gynecologic surgery.
We conducted a prospective healthcare improvement study to align transfusion practices with the American Society of Hematology's Choosing Wisely® campaign. Baseline transfusion rates were determined retrospectively for all major gynecologic surgical cases from 3/1/14 to 6/30/14. Data for the post-intervention period from 5/15/15 to 5/16/16 were captured prospectively. The primary outcome was transfusion within 72 h of surgery. Secondary outcomes included perioperative morbidity, mortality, number of units ordered per transfusion episode and cost.
We identified 1281 surgical cases, 334 in the baseline and 947 in the post-implementation cohort. The baseline cohort was noted to have a higher median estimated blood loss (100 v. 75 mL, P < 0.01). Otherwise, there were no differences in clinical or perioperative characteristics between the two cohorts. The perioperative transfusion rate decreased from 24% to 11% (adjusted OR 0.27, 95% CI 0.16 to 0.45; P < 0.001). The perioperative laparotomy transfusion rate decreased from 48% to 23% (adjusted OR 0.21, 95% CI 0.12, 0.37; P < 0.001). The number of occurrences in which more than one unit of blood was ordered at a time decreased from 65% to 23%, P < 0.001. The incidence of surgical site infections declined in the post-intervention group, otherwise there were no differences in 30-day mortality, cardiac, venous thromboembolism or readmission rates between the groups. The projected cost savings was $161,112 over the 12-month intervention period.
Implementation of an educational based transfusion reduction program was associated with substantial reductions in perioperative transfusions and cost without significant changes in morbidity or mortality.
评估妇科手术患者输血减少计划的疗效和经济影响。
我们进行了一项前瞻性医疗改进研究,以使输血实践与美国血液学会的明智选择®运动保持一致。回顾性确定所有主要妇科手术病例(从 2014 年 3 月 1 日至 6 月 30 日)的基线输血率。前瞻性捕获 2015 年 5 月 15 日至 2016 年 5 月 16 日的干预后数据。主要结果是手术 72 小时内输血。次要结果包括围手术期发病率、死亡率、每次输血的单位数和成本。
我们确定了 1281 例手术病例,基线组 334 例,实施后组 947 例。基线组的中位估计失血量更高(100 与 75ml,P < 0.01)。否则,两组之间在临床或围手术期特征方面没有差异。围手术期输血率从 24%降至 11%(调整后的 OR 0.27,95%CI 0.16 至 0.45;P < 0.001)。剖腹术输血率从 48%降至 23%(调整后的 OR 0.21,95%CI 0.12 至 0.37;P < 0.001)。一次订购超过一个单位血液的次数从 65%降至 23%,P < 0.001。干预后组的手术部位感染发生率下降,两组之间 30 天死亡率、心脏、静脉血栓栓塞或再入院率无差异。在干预期间的 12 个月内,预计可节省 161112 美元。
实施基于教育的输血减少计划与围手术期输血和成本的大量减少相关,而发病率或死亡率没有显著变化。